TITLE:
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

CONDITION:
Melanoma

INTERVENTION:
CC-5013

SUMMARY:

      Subjects are randomized to one of two treatment arms. All subjects are screened for
      eligibility within 28 days prior to randomization. The study consists of a treatment phase
      and a follow-up phase. Subjects are treated in repeating 4 week cycles.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  Understand and voluntarily sign an informed consent form

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Metastatic malignant melanoma now stage IV, relapsed or refractory to standard
             metastatic therapy

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 7 days of starting study drug

          -  Patients with active brain disease, or newly diagnosed brain metastases, within 4
             weeks prior to the start of study treatment are excluded.
      
